Fishmeal, plant protein, and fish oil substitution with single-cell ingredients in organic feeds for European sea bass (Dicentrarchus labrax)

publishedVersio

Effects of novel ingredients on growth performance in european sea bass, dicentrarchus labrax

publishedVersio

How to develop a national heart failure clinics network: a consensus document of the Hellenic Heart Failure Association

Heart failure (HF) is rapidly growing, conferring considerable mortality, morbidity, and costs. Dedicated HF clinics improve patient outcomes, and the development of a national HF clinics network aims at addressing this need at national level. Such a network should respect the existing health care infrastructures, and according to the capacities of hosting facilities, it can be organized into three levels. Establishing the continuous communication and interaction among the components of the network is crucial, while supportive actions that can enhance its efficiency include involvement of multidisciplinary health care professionals, use of structured HF-specific documents, such as discharge notes, patient information leaflets, and patient booklets, and implementation of an HF-specific electronic health care record and database platform

Beneficial Effects of Vaccination on Cardiovascular Events: Myocardial Infarction, Stroke, Heart Failure

Influenza and pneumococcal infections have been suggested to be potential risk factors for causing adverse cardiovascular events, especially in high-risk patients. Vaccination against respiratory infections in patients with established cardiovascular disease (CVD) could serve as a potential cost-effective intervention to improve their clinical outcomes and cardiac societies have encouraged it. Previous studies have shown that influenza vaccination reduce mortality, acute coronary syndromes and hospitalization in patients with coronary heart disease (CHD) and/or heart failure (HF). However, there is a paucity of randomized prospective clinical trials in the field of the pneumococcal vaccination, and additional higher-quality evidence is needed. Furthermore, questions around the role of vaccination in the primary prevention of CVD, the optimal dose and timing are largely unanswered. The pathophysiologic mechanism in which vaccination provides cardiovascular protection may be related to the modification of the immune-inflammatory model of atherogenesis. The present review summarizes the current evidence and understanding for vaccination against influenza and streptococcus pneumoniae in CHD, HF and stroke and highlights its beneficial effect in the reduction of adverse cardiovascular events. (C) 2018 S. Karger AG, Base

Molecular variation at the apolipoprotein B gene locus in relation to lipids and cardiovascular disease: a systematic meta-analysis

Apolipoprotein B (apoB) is the sole protein component of low-density lipoprotein (LDL) and is thought to play an important role in atherogenesis. We performed a meta-analysis of the associations between the three most frequently investigated polymorphisms (XbaI, signal peptide insertion/deletion, EcoRI) in the apolipoprotein B (APOB) gene, lipid parameters, and the risk of ischemic heart disease (IHD). We restricted our analysis to Caucasians. Homozygotes for the XbaI X+ allele had significantly elevated levels of LDL cholesterol (LDL-C) and apoB, but a decreased risk (OR=0.80; 95%CI: 0.66-0.96) of IHD. Homozygosity for the signal peptide deletion allele was associated with similarly increased levels of LDL-C and apoB, and with an increased risk of IHD (OR=1.30; 95%CI: 1.08-1.58). Subjects homozygous for the rare EcoRI allele had significantly decreased levels of total and LDL cholesterol, but unaltered risk of IHD. We conclude that all three polymorphic apoB sites are associated with altered lipid levels, but not necessarily with a consistently altered risk of IHD. These data suggest that the relationship between apoB levels, hypercholesterolemia and IHD risk cannot have a simple molecular basis in the apoB gen

Clinical and neurohormonal correlates and prognostic value of serum prolactin levels in patients with chronic heart failure

Hypothalamic axis deregulation is associated with clinical severity and depression in chronic heart failure (CHF). We investigated the relationship of serum prolactin, an indicator of hypothalamic axis function, to neurohomonal/immune activation and depressive symptoms in CHF as well as its prognostic value. Serum prolactin was determined in 180 patients with advanced CHF (aged 65 12 years, mean LVEF 27 7) along with natriuretic peptides (BNP), inflammatory cytokines, endothelial adhesion molecules, 6 min walk test (6MWT), and the Zung self-rating depression scale (SDS). Patients were followed for all-cause death or hospitalization for cardiovascular reasons for up to 8 months. Prolactin levels were significantly correlated with NYHA class (r 0.394, P 0.001), LVEF (r 0.314, P 0.001), 6MWT (r 0.353, P 0.001), BNP (r 0.374, P 0.001), Zung SDS (r 0.544, P 0.001), interleukin-6 (IL-6) (r 0.451, P 0.001), IL-10 (r 0.426, P 0.001), tumour necrosis factor (TNF)- (r 0.310, P 0.001), soluble Fas (r 0.333, P 0.001), soluble Fas-ligand (r 0.517, P 0.001), soluble intercellular adhesion molecule-1 (ICAM-1) (r 0.409, P 0.001), and soluble vascular cell adhesion molecule-1 (VCAM-1) (r 0.480, P 0.001). During follow-up, 119 patients (66) died or were hospitalized for cardiovascular events after a median time of 72 days (range 5220 days); these patients had higher baseline prolactin levels (10.2 5.7 vs. 6.7 4.3 ng/mL, P 0.001), and a prolactin value 4.5 ng/mL was associated with a higher rate of death or hospitalization (116 7 vs. 181 11 days, P 0.0001). In multivariate analysis, prolactin levels remained an independent predictor of death or hospitalization (4.5 vs. 4.5 ng/mL; odds ratio, 0.368; 95 confidence interval 0.1480.913; P 0.031), along with BNP (P 0.001) and 6MWT (P 0.020). Serum prolactin is associated with neurohormonal/immune activation and depressive symptoms and is an independent predictor of prognosis in advanced CHF